During pregnancy, the fetus is subject to complex interactions of biological and environmental factors that can influence developmental trajectories even into adulthood. Although several factors, such as maternal malnutrition and substance abuse, have been associated with offspring development, the mechanisms through which short- and long-term effects manifest in the fetus are not well understood. To this end, positron emission tomography (PET) imaging using preclinical models has been a promising and underutilized technique for investigating fetal exposure and physiology in utero with minimal invasiveness. Herein, we review the application of PET imaging to fetal medicine and survey the limitations and opportunities for future longitudinal studies of development. Over the past two decades, several studies have utilized preclinical PET in quantitative studies of maternal-fetal exchange dynamics of pharmaceuticals, environmental toxins, or drugs of abuse. Another application has shown [18F]FDG PET to be a potential biomarker for fetal glucose transport, hypoxia, and brain function in utero. In contrast, only a few studies have employed reversibly binding radioligands to quantify protein markers of dopaminergic signaling and synaptic density in the fetal brain. As PET technology continues to improve, our review highlights a future role for PET in longitudinal studies of fetal health and development.
BerglundLHalldinCLiljaA, et al.
11C‐methionine kinetics in pregnant rhesus monkeys studied by positron emission tomography: a new approach to feto‐maternal metabolism. Acta Obstet Gynecol Scand1984;
63: 641–645.
2.
Dow-EdwardsDLBenvenisteHBehnkeM, et al.
Neuroimaging of prenatal drug exposure. Neurotoxicol Teratol2006;
28: 386–402.
3.
ZhangZImperialMZPatilea-VranaGI, et al.
Development of a novel maternal-fetal physiologically based pharmacokinetic model I: insights into factors that determine fetal drug exposure through simulations and sensitivity analyses. Drug Metab Dispos2017;
45: 920–938.
4.
MerrickMTFordDCPortsKA, et al.
Vital signs: estimated proportion of adult health problems attributable to adverse childhood experiences and implications for prevention – 25 states, 2015–2017. Mmwr Morb Mortal Wkly Rep2019;
68: 999–1005.
5.
RossEJGrahamDLMoneyKM, et al.
Developmental consequences of fetal exposure to drugs: what we know and what we still must learn. Neuropsychopharmacology2015;
40: 61–87.
6.
Palma-GudielHCórdova-PalomeraAEixarchE, et al.
Maternal psychosocial stress during pregnancy alters the epigenetic signature of the glucocorticoid receptor gene promoter in their offspring: a meta-analysis. Epigenetics2015;
10: 893–902.
7.
LoJOD'MelloRJWatchL, et al.
An epigenetic synopsis of parental substance use. Epigenomics2023;
15: 453–473.
8.
VolkowNDGordonJABianchiDW, et al.
The HEALthy brain and child development study (HBCD): NIH collaboration to understand the impacts of prenatal and early life experiences on brain development. Dev Cogn Neurosci2024;
69: 101423.
9.
NygaardESlinningKMoeV, et al.
Mental health in youth prenatally exposed to opioids and poly-drugs and raised in permanent foster/adoptive homes: a prospective longitudinal study. Early Hum Dev2020;
140: 1–8.
10.
WenXLawalODBelvisoN, et al.
Association between prenatal opioid exposure and neurodevelopmental outcomes in early childhood: a retrospective cohort study. Drug Saf2021;
44: 863–875.
11.
CarterAM.Animal models of human placentation – a review. Placenta2007;
28 Suppl A: S41–S47.
12.
HerrickEJBordoniB.Embryology, Placenta [Updated 2023 May 1]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2024.
13.
BerglundLGebremedhinMLindbergB, et al.
Placental transfer of methionine during protein restriction in the rhesus monkey studied by position emission tomography. Placenta1989;
10: 387–397.
14.
HartvigPLindbergBSLiljaA, et al.
Positron emission tomography in studies on fetomaternal disposition of opioids. Dev Pharmacol Ther1989;
12: 74–80.
15.
BenvenisteH, et al.
Maternal and fetal 11 C-Cocaine uptake and kinetics measured in vivo by combined PET and MRI in pregnant nonhuman primates. J Nucl Med2005;
46: 312–320.
16.
BartlettRMMuraliDNicklesRJ, et al.
Assessment of fetal brain uptake of paraquat in utero using in vivo PET/CT imaging. Toxicol Sci2011;
122: 551–556.
17.
BartelsJLFernandezSRAwedaTA, et al.
Comparative uptake and biological distribution of [18F]-labeled C6 and C8 perfluorinated alkyl substances in pregnant mice via different routes of administration. Environ Sci Technol Lett2020;
7: 665–671.
18.
OvergaardMDDuvaldCSVendelboMH, et al.
Biodistribution of [11C]-metformin and mRNA expression of placentae metformin transporters in the pregnant chinchilla. Contrast Media Mol Imaging2019;
2019: 9787340.
19.
TakamuraYKatoIFujita-TakahashiM, et al.
Teratogenicity and fetal-transfer assessment of the retinoid X receptor agonist bexarotene. ACS Pharmacol Transl Sci2022;
5: 811–818.
20.
Ben EliezerN, et al.
Novel multimodal molecular imaging of vitamin H (biotin) transporter activity in the murine placenta. Sci Rep2020;
10: 20767.
21.
JulianoRLLingV.A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta1976;
455: 152–162.
22.
JoshiKKMatlackTLRongoC.Dopamine signaling promotes the xenobiotic stress response and protein homeostasis. EMBO J2016;
35: 1885–1901.
23.
SasongkoLLinkJMMuziM, et al.
Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther2005;
77: 503–514.
24.
EyalSChungFSMuziM, et al.
Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate. J Nucl Med2009;
50: 798–806.
25.
ChungFSEyalSMuziM, et al.
Positron emission tomography imaging of tissue P-glycoprotein activity during pregnancy in the non-human primate. Br J Pharmacol2010;
159: 394–404.
26.
KeABEyalSChungFS, et al.
Modeling cyclosporine a inhibition of the distribution of a P-glycoprotein PET ligand, 11-Cverapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: Impact of tissue blood flow and site of inhibition. J Nucl Med2013;
54: 437–446.
27.
MichelsenTMHolmeAMHolmMB, et al.
Uteroplacental glucose uptake and fetal glucose consumption: a quantitative study in human pregnancies. J Clin Endocrinol Metab2019;
104: 873–882.
28.
NorrisAWWangCYaoJ, et al.
Effect of insulin and dexamethasone on fetal assimilation of maternal glucose. Endocrinology2011;
152: 255–262.
29.
LumeyLHSteinADKahnHS, et al.
Cohort profile: the Dutch hunger winter families study. Int J Epidemiol2007;
36: 1196–1204.
BenvenisteHFowlerJSRooneyWD, et al.
Maternal-fetal in vivo imaging: a combined PET and MRI study. J Nucl Med2003;
44: 1522–1530.
32.
SawatzkeABNorrisAWSpyropoulosF, et al.
PET/CT imaging reveals unrivaled placental avidity for glucose compared to other tissues. Placenta2015;
36: 115–120.
33.
YaoJWangCWalshSA, et al.
Localized fetomaternal hyperglycemia: Spatial and kinetic definition by positron emission tomography. PLoS One2010;
5: e12027.
34.
TchirikovMTchirikovMBuchertR, et al.
Glucose uptake in the placenta, fetal brain, heart and liver related to blood flow redistribution during acute hypoxia. J Obstet Gynaecol Res2011;
37: 979–985.
35.
ZheleznyakAGarbowJRNeemanM, et al.
E. Preclinical positron emission tomographic imaging of acute hyperoxia therapy of chronic hypoxia during pregnancy. Mol Imaging2015;
14: 366–372.
36.
McCarthyDLuerasPBhidePG.Elevated dopamine levels during gestation produce region-specific decreases in neurogenesis and subtle deficits in neuronal numbers. Brain Res2007;
1182: 11–25.
37.
BorisovaNASapronovaAYProshlyakovaEV, et al.
Ontogenesis of the hypothalamic catecholaminergic system in rats: synthesis, uptake and release of catecholamines. Neuroscience1991;
43: 223–229.
38.
BenvenisteHFowlerJSRooneyWD, et al.
Cocaine is pharmacologically active in the nonhuman primate fetal brain. Proc Natl Acad Sci U S A2010;
107: 1582–1587.
39.
FinnemaSJNabulsiNBEidT, et al.
Imaging synaptic density in the living human brain. Sci Transl Med2016;
8: 348ra96.
40.
RossanoSToyonagaTBergE, et al.
Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET). Eur J Nucl Med Mol Imaging2022;
49: 3679–3691.
41.
BettinardiVCastiglioniIDe BernardiE, et al.
PET quantification: strategies for partial volume correction. Clin Transl Imaging2014;
2: 199–218.
42.
MandevilleJBEfthimiouNWeigand-WhittierJ, et al.
Partial volume correction of PET image data using geometric transfer matrices based on uniform B-splines. Phys Med Biol2024;
69.
43.
BartlettRMNicklesRJBarnhartTE, et al.
Fetal dose estimates for 18F-fluoro-l-thymidine using a pregnant monkey model. J Nucl Med2010;
51: 288–292.
44.
HuttenlocherPR.Synaptic density in human frontal cortex – developmental changes and effects of aging. Brain Res1979;
163: 195–205.
45.
SakaiJ.Core concept: how synaptic pruning shapes neural wiring during development and, possibly, in disease. Proc Natl Acad Sci U S A2020;
117: 16096–16099.
46.
Zanotti-FregonaraPKoroscilTMMantilJ, et al.
Radiation dose to the fetus from [18F]-FDG administration during the second trimester of pregnancy. Health Phys2012;
102: 217–219.
47.
Zanotti-FregonaraPChampionCTrébossenR, et al.
Estimation of the β+ dose to the embryo resulting from 18F-FDG administration during early pregnancy. J Nucl Med2008;
49: 679–682.
48.
Zanotti-FregonaraPJanSChampionC, et al.
In vivo quantification of 18f-fdg uptake in human placenta during early pregnancy. Health Phys2009;
97: 82–85.
49.
Zanotti-FregonaraPIshiguroTYoshiharaK, et al.
18F-FDG fetal dosimetry calculated with PET/MRI. J Nucl Med2022;
63: 1592–1597.
50.
TakalkarAMKhandelwalALokitzS, et al.
18F-FDG PET in pregnancy and fetal radiation dose estimates. J Nucl Med2011;
52: 1035–1040.
51.
SteenvoordePPauwelsEKHardingLK, et al.
Diagnostic nuclear medicine and risk for the fetus. Eur J Nucl Med1998;
25: 193–199.
52.
Zanotti-FregonaraPJanSTaiebD, et al.
Absorbed 18F-FDG dose to the fetus during early pregnancy. J Nucl Med2010;
51: 803–805.
53.
OtakeMSchullWJ.Radiation-related small head sizes among prenatally exposed A-bomb survivors. Int J Radiat Biol1993;
63: 255–270.
54.
SreetharanSThomeCTharmalingamS, et al.
Ionizing radiation exposure during pregnancy: effects on postnatal development and life. Radiat Res2017;
187: 647–658.
55.
LiHBadawiRDCherrySR, et al.
Performance characteristics of the NeuroEXPLORER, a next-generation human brain PET/CT imager. J Nucl Med2024;
65: 1320–1326.
56.
JonesTBudingerTF.The potential for low-dose functional studies in maternal-fetal medicine using PET/MR imaging. J Nucl Med2013;
54: 2016–2017.
57.
LiAYangBNaganawaM, et al.
Dose reduction in dynamic synaptic vesicle glycoprotein 2A PET imaging using artificial neural networks. Phys Med Biol2023;
68.
58.
MirandaABertoglioDStroobantsS, et al.
Translation of preclinical PET imaging findings: challenges and motion correction to overcome the confounding effect of anesthetics. Front Med (Lausanne)2021;
8: 753977.
59.
ZeissCJ.Comparative milestones in rodent and human postnatal central nervous system development. Toxicol Pathol2021;
49: 1368–1373.
60.
ZhangY-QLinW-PHuangL-P, et al.
Dopamine D2 receptor regulates cortical synaptic pruning in rodents. Nat Commun2021;
12: 6444.
61.
KongstorpMBogenILSteinslandS, et al.
Prenatal exposure to methadone or buprenorphine alters µ-opioid receptor binding and downstream signaling in the rat brain. Int J Dev Neurosci2020;
80: 443–453.
62.
WachmanEMHayesMJBrownMS, et al.
Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA2013;
309: 1821–1827.
